Search
OPC-14523
go.drugbank.com/drugs/DB05422ExperimentalOPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.
Tibolone
go.drugbank.com/drugs/DB09070ApprovedInvestigationalTibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and progestogenic properties.
Protocatechualdehyde
go.drugbank.com/drugs/DB11268ApprovedProtocatechualdehyde possesses antiproliferative and pro-apoptotic properties against human breast cancer cells and colorectal cancer cells by reducing the expression of pro-oncogenes β-catenin and cyclin
Acenocoumarol
go.drugbank.com/drugs/DB01418ApprovedInvestigationalCoumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation.
Cenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigationalCenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.
Lifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigationalimmunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341] Lifileucel was granted accelerated approval by
Bismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnThe use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.
Monopotassium phosphate
go.drugbank.com/drugs/DB09413ApprovedInvestigationalVet approvedIt can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low.
Ocriplasmin
go.drugbank.com/drugs/DB08888ApprovedWithdrawnOcriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system.
Benfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnIt was patented and manufactured by a French pharmaceutical company Servier. The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.